颈动脉支架术中替格瑞洛与氯吡格雷围术期双联抗血小板治疗的疗效与安全性
基于VQI登记数据,比较经股动脉颈动脉支架术(tfCAS)和经颈动脉血运重建术(TCAR)中,阿司匹林/替格瑞洛与阿司匹林/氯吡格雷的围术期双联抗血小板治疗效果。倾向评分匹配后,tfCAS中替格瑞洛组出血风险更高,但使用鱼精蛋白时两组出血无差异;TCAR中两组结局无显著差异。
要点
- tfCAS中替格瑞洛组出血风险显著高于氯吡格雷组(5.8% vs 2.8%)。
- 使用鱼精蛋白的tfCAS亚组中,替格瑞洛与氯吡格雷的卒中/死亡和出血风险均无差异。
- TCAR中两组卒中/死亡、卒中、死亡和出血风险均无显著差异。
核心结论
- 在tfCAS中,替格瑞洛较氯吡格雷增加出血风险,但使用鱼精蛋白时该差异消失。
- 在TCAR中,替格瑞洛与氯吡格雷的疗效和安全性无显著差异。
- 使用鱼精蛋白时,替格瑞洛可作为氯吡格雷的合理替代。
研究设计与样本
- 回顾性队列研究,使用Vascular Quality Initiative登记数据(2016年1月至2021年3月)。
- 纳入17,731例tfCAS患者和17,946例TCAR患者,按1:3倾向评分匹配比较阿司匹林/替格瑞洛与阿司匹林/氯吡格雷。
主要发现
- tfCAS匹配队列中,卒中/死亡复合终点:替格瑞洛组4.1% vs 氯吡格雷组2.6%(RR 1.5,95%CI 0.88-2.7)。
- tfCAS匹配队列中,出血:替格瑞洛组5.8% vs 氯吡格雷组2.8%(RR 2.0,95%CI 1.2-3.2)。
- tfCAS使用鱼精蛋白亚组(297例),卒中/死亡:1.5% vs 3.9%(RR 0.38,95%CI 0.05-3.0),出血:3.0% vs 2.6%(RR 1.1,95%CI 0.24-5.5)。
- TCAR匹配队列中,卒中/死亡:0.7% vs 1.4%(RR 0.53,95%CI 0.16-1.8),出血:1.2% vs 1.6%(RR 0.75,95%CI 0.28-2.0)。
- TCAR使用鱼精蛋白亚组(1429例),卒中/死亡:0.8% vs 1.2%(RR 0.68,95%CI 0.20-2.4),出血:0.6% vs 1.4%(RR 0.39,95%CI 0.09-1.7)。
临床怎么用
- 对于接受tfCAS或TCAR的患者,若术中使用鱼精蛋白,可考虑用替格瑞洛替代氯吡格雷。
- 在未使用鱼精蛋白的tfCAS患者中,替格瑞洛出血风险较高,需谨慎选择。
局限性
- 样本量有限,尤其替格瑞洛组患者数量较少。
- 作者建议待更多患者数据可用时重复分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clopidogrel resistance is associated with increased periprocedural neurologic events after carotid artery stenting (CAS). Ticagrelor offers an improved resistance profile; however, its bleeding risk has not been assessed with CAS. Therefore, we examined the efficacy and safety of perioperative dual antiplatelet therapy with aspirin/ticagrelor vs aspirin/clopidogrel in patients undergoing transfemoral carotid artery stenting (tfCAS) or transcarotid artery revascularization (TCAR). METHODS: We identified all patients who underwent tfCAS or TCAR in the Vascular Quality Initiative registry from January 2016 to March 2021. We stratified patients by procedure and assessed outcomes using 1:3 propensity score-matched cohorts of patients who received perioperative aspirin/ticagrelor vs aspirin/clopidogrel. The primary efficacy outcome was a composite endpoint of in-hospital stroke/death, and the primary safety outcome was access-related bleeding. As a secondary analysis, we assessed these outcomes after stratifying each cohort by intraoperative protamine use. RESULTS: Among 17,731 tfCAS patients, 593 (3.3%) received aspirin/ticagrelor and 11,404 (64%) received aspirin/clopidogrel. For the 2065 matched patients, no significant differences were found in the composite endpoint of stroke/death (aspirin/ticagrelor, 4.1%; vs aspirin/clopidogrel, 2.6%; relative risk [RR],1.5; 95% confidence interval [CI], 0.88-2.7) or in the individual endpoints of stroke (2.9% vs 1.8%; RR, 1.6; 95% CI, 0.87-3.0) or death (1.7% vs 1.1%; RR, 1.6; 95% CI, 0.71-3.5). However, aspirin/ticagrelor was associated with a higher risk of bleeding (5.8% vs 2.8%; RR, 2.0; 95% CI, 1.2-3.2). In a subgroup analysis of 297 tfCAS patients (14%) who received intraoperative protamine, no differences remained in stroke/death (1.5% vs 3.9%; RR, 0.38; 95% CI, 0.05-3.0), and there was no longer a difference in bleeding (3.0% vs 2.6%; RR, 1.1; 95% CI, 0.24-5.5). Among 17,946 TCAR patients, 453 (2.5%) received aspirin/ticagrelor and 13,696 (76%) received aspirin/clopidogrel. For the 1618 matched patients, no differences were found in stroke/death (0.7% vs 1.4%; RR, 0.53; 95% CI, 0.16-1.8), stroke (0.2% vs 1.2%; RR, 0.20; 95% CI, 0.03-1.5), death (0.5% vs 0.2%; RR, 3.0; 95% CI, 0.42-21), or bleeding (1.2% vs 1.6%; RR, 0.75; 95% CI, 0.28-2.0). For the 1429 TCAR patients (88%) who received protamine, no differences were found in stroke/death (0.8% vs 1.2%; RR, 0.68; 95% CI, 0.20-2.4) or bleeding (0.6% vs 1.4%; RR, 0.39; 95% CI, 0.09-1.7). CONCLUSIONS: Compared with aspirin/clopidogrel, aspirin/ticagrelor was associated with a potentially lower risk of stroke/death and bleeding complications after CAS in cases in which protamine was used but a higher risk of these outcomes in the absence of protamine. Given our limited sample size, our analysis should be repeated when more patients are available for study. However, our findings suggest that aspirin/ticagrelor could be a reasonable alternative to aspirin/clopidogrel for both tfCAS and TCAR when protamine is used.
引用
- Marcaccio CL, Patel PB, Liang P, et al. Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting. J Vasc Surg. 2021. PMID: 34655685. doi:10.1016/j.jvs.2021.09.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。